Precision and Regenerative Medicine and Ionian Area, Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy.
Pediatr Nephrol. 2024 Jun;39(6):1685-1707. doi: 10.1007/s00467-023-06046-1. Epub 2023 Sep 20.
Focal segmental glomerulosclerosis (FSGS) is a complex disease which describes different kinds of kidney defects, not exclusively linked with podocyte defects. Since nephrin mutation was first described in association with early-onset nephrotic syndrome (NS), many advancements have been made in understanding genetic patterns associated with FSGS. New genetic causes of FSGS have been discovered, displaying unexpected genotypes, and recognizing possible site of damage. Many recent large-scale sequencing analyses on patients affected by idiopathic chronic kidney disease (CKD), kidney failure (KF) of unknown origin, or classified as FSGS, have revealed collagen alpha IV genes, as one of the most frequent sites of pathogenic mutations. Also, recent interest in complex and systemic lysosomal storage diseases, such as Fabry disease, has highlighted GLA mutations as possible causes of FSGS. Tubulointerstitial disease, recently classified by KDIGO based on genetic subtypes, when associated with UMOD variants, may phenotypically gain FSGS features, as well as ciliopathy genes or others, otherwise leading to completely different phenotypes, but found carrying pathogenic variants with associated FSGS phenotype. Thus, glomerulosclerosis may conceal different heterogeneous conditions. When a kidney biopsy is performed, the principal objective is to provide an accurate diagnosis. The broad spectrum of phenotypic expression and genetic complexity is demonstrating that a combined path of management needs to be applied. Genetic investigation should not be reserved only to selected cases, but rather part of medical management, integrating with clinical and renal pathology records. FSGS heterogeneity should be interpreted as an interesting opportunity to discover new pathways of CKD, requiring prompt genotype-phenotype correlation. In this review, we aim to highlight how FSGS represents a peculiar kidney condition, demanding multidisciplinary management, and in which genetic analysis may solve some otherwise unrevealed idiopathic cases. Unfortunately there is not a uniform correlation between specific mutations and FSGS morphological classes, as the same variants may be identified in familial cases or sporadic FSGS/NS or manifest a variable spectrum of the same disease. These non-specific features make diagnosis challenging. The complexity of FSGS genotypes requires new directions. Old morphological classification does not provide much information about the responsible cause of disease and misdiagnoses may expose patients to immunosuppressive therapy side effects, mistaken genetic counseling, and misguided kidney transplant programs.
局灶节段性肾小球硬化症(FSGS)是一种复杂的疾病,描述了不同类型的肾脏缺陷,不仅仅与足细胞缺陷有关。自从首次描述了nephrin 突变与早发性肾病综合征(NS)有关以来,人们在理解与 FSGS 相关的遗传模式方面取得了许多进展。已经发现了新的 FSGS 遗传原因,显示出意想不到的基因型,并识别出可能的损伤部位。最近对患有特发性慢性肾脏病(CKD)、不明原因的肾衰竭(KF)或归类为 FSGS 的患者进行的许多大型测序分析显示,胶原 alpha IV 基因是最常见的致病突变之一。此外,最近对复杂和系统性溶酶体贮积病(如 Fabry 病)的关注突出了 GLA 突变可能是 FSGS 的原因。肾小管间质疾病,最近根据遗传亚型由 KDIGO 分类,当与 UMOD 变体相关时,可能会表现出 FSGS 的特征,以及纤毛病基因或其他基因,否则会导致完全不同的表型,但发现携带相关 FSGS 表型的致病变体。因此,肾小球硬化可能隐藏着不同的异质性条件。当进行肾活检时,主要目的是提供准确的诊断。表型表达和遗传复杂性的广泛范围表明,需要应用综合的管理途径。遗传研究不应仅保留给选定的病例,而应成为医疗管理的一部分,与临床和肾脏病理学记录相结合。FSGS 的异质性应被解释为发现新的 CKD 途径的有趣机会,需要及时进行基因型-表型相关性研究。在这篇综述中,我们旨在强调 FSGS 如何代表一种特殊的肾脏疾病,需要多学科管理,其中遗传分析可能解决一些否则无法解释的特发性病例。不幸的是,特定突变与 FSGS 形态学分类之间没有统一的相关性,因为相同的变体可能在家族性病例或散发性 FSGS/NS 中被识别,或者表现出相同疾病的不同谱。这些非特异性特征使得诊断具有挑战性。FSGS 基因型的复杂性需要新的方向。旧的形态学分类并不能提供关于疾病原因的太多信息,错误的诊断可能使患者暴露于免疫抑制治疗的副作用、错误的遗传咨询和误导性的肾脏移植计划。